Founders who still run their companies tend to think in decades, not quarters, which can matter when inflation, interest rates and energy politics keep shifting and bond yields, housing data and trade flows pull markets in different directions. The Founder-Led Companies screener focuses on leaders with real skin in the game, so their own wealth rises or falls with yours. That alignment can help keep execution focused when central bank paths or consumer demand look uncertain. In this article, you will see 3 founder-led stocks from the screener that stand out for deeper analysis.

Samsara (IOT)

Overview: Samsara connects vehicles, equipment, and industrial sites to its cloud platform using IoT devices and cameras, then turns that data into AI powered tools for safety, telematics, asset tracking, and site visibility. Its software is used across sectors like transportation, construction, logistics, utilities, and public services to monitor operations in real time and manage costs, safety, and compliance.

Operations: Samsara generates about US$1.73b in revenue primarily from Software & Programming, with roughly US$1.48b coming from the United States and US$255.55m from other regions.

Market Cap: US$22.33b

Samsara provides exposure to the data and AI side of physical operations, with an ARR base of US$1.89b, net revenue retention above 115%, and customer case studies that point to reductions in accidents and losses. At the same time, the stock trades on a premium P/S multiple, insiders have been selling, and funding relies on higher risk external borrowing. Expectations are already high and balance sheet risk is not trivial. With profitability only recently achieved and earnings growth forecasts above 20% a year, the key question for investors is whether Samsara’s data moat and expanding AI product set justify paying a premium for that growth or indicate a need for caution at current levels.

Samsara’s AI powered operations data, rich ARR base and premium P/S all point to a story investors may be only half seeing. Before you judge the trade off between growth and balance sheet risk, review the 2 key rewards and 1 important warning sign

Slide Insurance Holdings (SLDE)

Overview: Slide Insurance Holdings focuses on homeowners and other coastal property insurance in the United States, using data driven underwriting and reinsurance programs to cover risks in hurricane exposed states while also providing reinsurance and agency services.

Operations: Slide Insurance Holdings generates about US$1.26b in revenue from insurance activities, all from the United States.

Market Cap: US$2.35b

Slide Insurance Holdings stands out because it combines strong recent earnings power with a focus on one of the hardest areas of the market to insure, coastal property. Earnings grew very quickly, margins are high at 38.9%, and return on equity has been outstanding, yet the stock trades on a low P/E compared with peers. At the same time, the business is tightly linked to hurricane seasons, Florida regulation, and a relatively young management and board, with all funding coming from higher risk external borrowing. For investors willing to weigh that trade off, the mix of disciplined reinsurance, share buybacks and expansion into new coastal states could be the part of the Slide Insurance story they are not yet fully pricing in.

Slide Insurance’s high margins, strong recent earnings and low P/E hint at a story the market may be misreading. The full 3 key rewards and 2 important warning signs (1 is major!) could reveal why hurricane seasons are only half the equation.

China Medical System Holdings (SEHK:867)

Overview: China Medical System Holdings is a Hong Kong headquartered pharmaceutical group that manufactures, markets, and promotes a wide range of prescription drugs in China across cardiovascular, gastroenterology, dermatology, eye care, and pain management. It often partners to bring new therapies such as biologics, injectables, and specialty treatments to the domestic market.

Operations: China Medical System Holdings generates roughly CN¥7.17b from its Integrated Business and CN¥1.07b from its Skin Health Business, with total revenue of about CN¥8.21b coming from the PRC after eliminations.

Market Cap: HK$29.46b

China Medical System Holdings looks interesting because the stock trades well below one widely used fair value estimate, analysts collectively see upside, and earnings are forecast to grow just over 21% a year even after a period when profits declined and margins compressed from 21.7% to 18.1%. At the same time, all funding comes from higher risk external borrowing and return on equity is modest. This means the expanding pipeline of approved and late stage drugs like Silevimig Injection and CMS-D001 Tablets will need to prove they can convert new therapies into durable cash flows. If that pipeline execution and the share buyback plan play out as hoped, today’s pricing may not reflect the full story around China Medical System’s potential.

China Medical System’s low pricing compared with one fair value estimate and a growing pipeline suggest the market may be missing something. Get the fuller picture in the full narrative for China Medical System Holdings

The three founder-led stocks here are only a starting point, with the full screener surfacing 1,452 more companies whose leaders also have their own capital on the line and narratives that may be just as compelling as what you have seen so far on this page through the Founder-Led Companies screener. Use Simply Wall St to identify and analyze the specific catalysts and founder narratives that matter to you, so you can focus on founder-led ideas that best match your highest conviction.

Take Control of Your Investment Journey

If Samsara or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before Everyone Else?

Fresh ideas move first, and the stocks with real breakout potential rarely stay under the radar for long. Scan these curated lists before momentum is fully caught and act now.

• Spot cash generative companies with sturdy balance sheets using the curated list of solid balance sheet and fundamentals (47 results) while they are still flying under most investors' radar.
• Follow the AI build out by tracking critical picks in the 54 AI infrastructure stocks before demand for chips, data centers and power links completes their repricing process.
• Consider positioning ahead of the robotics wave with hand picked opportunities from the 33 robotics and automation stocks while automation spending trends are still delivering new developments to the market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.